Form 4: Edwards Lifesciences Executive Sells Shares for Taxes

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, disposed of 362 shares to cover tax obligations on May 11, 2026.

Summary

• Daniel J. Lippis, Corporate Vice President of Transcatheter Aortic Valve Replacement (TAVR), disposed of 362 shares of common stock.
• The transaction occurred on May 11, 2026, at a price of $79.96 per share.
• The disposal was categorized as Code F, which indicates the payment of tax liability by withholding securities incident to the vesting of equity awards.
• Following this transaction, the reporting person directly beneficially owns 40,410.9103 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event with no impact on the company's fundamental value or strategic direction.

Positives

• The reporting person maintains a significant direct ownership stake of over 40,000 shares.
• The transaction was non-discretionary and specifically intended to satisfy tax withholding obligations rather than being a market-timed sale.

Negatives

• There is a minor reduction in the total number of shares held by a key executive.

Risks

• No specific risks were disclosed in this regulatory transaction report.

Future Outlook

No forward-looking statements or financial guidance were provided in this document.

Management Comments

• No specific management commentary was provided in this regulatory document.

Industry Context

StockSavvy.ai notes that 'Code F' transactions are standard administrative procedures in the medical technology industry, where executives use shares to cover tax burdens arising from the vesting of equity awards.

Comparison to Industry Standards

• The use of share withholding for taxes is consistent with practices at peer companies such as Medtronic plc and Boston Scientific Corporation.
• Executive ownership levels remain high relative to the transaction size, which is typical for established large-cap healthcare companies.

Related Party Transactions

• The reporting person is an officer of the issuer, making this a related party transaction under Section 16 of the Securities Exchange Act.

Stakeholder Impact

• Minimal impact on shareholders due to the small volume of shares involved relative to total shares outstanding.

Next Steps

• No future actions or milestones were mentioned in this regulatory document.

Key Dates

Recommendation

This routine tax-related transaction by an insider does not provide new material information that would alter a long-term investment thesis.

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Medical Devices, TAVR, Executive Compensation, Daniel Lippis